TARS - Company ID 0001819790
The table below shows Tarsus Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $451.36M | $182.95M | $17.45M | $25.82M | $57.03M | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $64.32M | $53.39M | $50.31M | $42.62M | $41.71M | $18.83M |
| SG&A |
Tarsus Pharmaceuticals, Inc. reported annual revenue of $451.36M for fiscal year 2025. That is up 146.7% from $182.95M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $427.32M |
| $237.31M |
| $108.70M |
| $44.95M |
| $25.40M |
| $8.17M |
| Operating income | -$70.97M | -$120.57M | -$143.16M | -$62.71M | -$12.16M | -$27.00M |
| Income tax | $2.06M | $0.00 | $0.00 | -$4.00K | $55.00K | $1.00K |
| Net income | -$66.00M | -$116.00M | -$136.00M | -$62.09M | -$13.83M | -$26.81M |
| EPS (diluted) | -$1.59 | -$3.07 | -$4.62 | -$2.52 | -$0.67 | -$4.32 |